NCT04580745View on ClinicalTrials.gov

Study of MORF 057 to Evaluate Single and Multi Ascending Doses in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

67

Participants

Timeline

Start Date

September 23, 2020

Primary Completion Date

March 31, 2021

Study Completion Date

April 12, 2021

Conditions
Healthy Volunteers
Interventions
DRUG

MORF-057

"SAD: Subjects will be assigned to one of five planned dose cohorts and receive single doses of MORF-057.~Food Effect: Subjects will receive single dose administration of MORF-057 in fed and fasted states.~MAD: Subjects will be assigned to one of three planned dose cohorts and receive multiple doses of MORF-057."

DRUG

Placebo for MORF-057

"SAD: Subjects will be assigned to one of five planned dose cohorts and receive single doses of placebo.~MAD: Subjects will be assigned to one of three planned dose cohorts and receive multiple doses of placebo."

Trial Locations (1)

45227

Medpace, Cincinnati

All Listed Sponsors
lead

Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)

INDUSTRY

NCT04580745 - Study of MORF 057 to Evaluate Single and Multi Ascending Doses in Healthy Volunteers | Biotech Hunter | Biotech Hunter